logo BDSP

Base documentaire

  1. Detection of latent prostate cancer from routine screening : comparison with breast cancer screening. Commentary.

    Article - En anglais


    One criticism of routine prostate cancer screening is the possibility that latent prostate cancer would be detected and treated in men who would otherwise never need treatment for their prostate cancer.

    This increase in latent cancer detection with screening could lead to overtreatment, with its resulting increases in morbidity, mortality, and health care costs.

    In contrast, breast cancer screening is widely accepted, and there is little concern about latent breast cancer detection and overtreatment of breast cancer due to screening.

    This study compares the detection of latent prostate cancer from screening with the detection of latent cancer in an established cancer screening program (breast cancer screening) and examines the risk that screening leads to an increase in detection of latent cancer over traditional methods of detection for both breast and prostate cancer.


    The present study reviews outcomes data from several large prostate and breast cancer screening trials.

    The natural history of latent prostate and breast cancer is then reviewed.

    By applying this information, the rate of latent prostate cancer detection and latent breast cancer detection with screening is compared.


    Recent large-scale prostate cancer screening studies have reported a latent cancer detection rate of 2.9% to 8.0%.

    Mots-clés Pascal : Epithélioma, Prostate, Stade précoce, Glande mammaire, Etude comparative, Dépistage, Diagnostic, Homme, Mâle, Femelle, Etats Unis, Amérique du Nord, Amérique, Appareil urinaire pathologie, Appareil génital mâle pathologie, Prostate pathologie, Tumeur maligne, Glande mammaire pathologie

    Mots-clés Pascal anglais : Carcinoma, Prostate, Early stage, Mammary gland, Comparative study, Medical screening, Diagnosis, Human, Male, Female, United States, North America, America, Urinary system disease, Male genital diseases, Prostate disease, Malignant tumor, Mammary gland diseases

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0593414

    Code Inist : 002B30A03B. Création : 01/03/1996.